[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

ALXO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 50.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $93,147.84

ALX Oncology Insider Trading History Chart

ALX Oncology Share Price & Price History

^$12.26

▲ +3.01 (32.54%)

As of 12/8/2023 01:00 AM ET

Days: 30 | 90 | 365

Trading Experts Call It “The Perfect Tesla Trade”

From Wealthpress | Ad

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

Click here for details,

ALX Oncology Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/6/2023	Shelly Pinto	CAO	Sell	7,345	$6.52	$47,889.40	55,713
6/30/2023	Jaume Pons	CEO	Sell	3,208	$7.34	$23,546.72	536,538
6/30/2023	Peter S. Garcia	CFO	Sell	887	$7.34	$6,510.58	54,738
6/30/2023	Shelly Pinto	CAO	Sell	466	$7.34	$3,420.44	63,058
6/30/2023	Sophia Randolph	Insider	Sell	1,605	$7.34	$11,780.70	281,477
12/13/2021	Jason Lettmann	Director	Sell	325,377	$27.36	$8,902,314.72
12/13/2021	Lsv Associates, Llc	Major Shareholder	Sell	48,390	$26.61	$1,287,657.90
12/10/2021	Lsv Associates, Llc	Major Shareholder	Sell	26,274	$31.31	$822,638.94
12/9/2021	Jason Lettmann	Director	Sell	76,905	$32.03	$2,463,267.15
12/8/2021	Lsv Associates, Llc	Major Shareholder	Sell	42,458	$33.25	$1,411,728.50
11/22/2021	Sophia Randolph	Insider	Sell	14,884	$36.77	$547,284.68
10/19/2021	Jaume Pons	CEO	Sell	16,700	$54.29	$906,643.00
10/18/2021	Peter S. Garcia	CFO	Sell	7,229	$55.44	$400,775.76
10/11/2021	Sophia Randolph	Insider	Sell	7,387	$60.97	$450,385.39
9/20/2021	Jaume Pons	CEO	Sell	16,700	$74.38	$1,242,146.00
9/16/2021	Peter S. Garcia	CFO	Sell	1,426	$80.43	$114,693.18	10,757
9/10/2021	Sophia Randolph	Insider	Sell	7,387	$77.66	$573,674.42	163,302
8/23/2021	Peter S. Garcia	CFO	Sell	60,000	$74.15	$4,449,000.00
8/19/2021	Jaume Pons	CEO	Sell	16,700	$61.28	$1,023,376.00
8/17/2021	Peter S. Garcia	CFO	Sell	10,000	$66.23	$662,300.00
7/19/2021	Jaume Pons	CEO	Sell	16,700	$54.57	$911,319.00	509,946
7/12/2021	Sophia Randolph	Insider	Sell	7,387	$54.90	$405,546.30
6/21/2021	Jaume Pons	CEO	Sell	16,700	$58.59	$978,453.00	521,599
5/19/2021	Jaume Pons	CEO	Sell	16,700	$55.71	$930,357.00	544,146
4/19/2021	Jaume Pons	CEO	Sell	16,700	$57.63	$962,421.00	556,016
4/12/2021	Sophia Randolph	Insider	Sell	7,387	$59.43	$439,009.41	198,234
3/22/2021	Jaume Pons	CEO	Sell	16,700	$68.49	$1,143,783.00	568,046
3/10/2021	Sophia Randolph	Insider	Sell	7,387	$74.34	$549,149.58	207,227
12/14/2020	G. Walmsley Graham	Director	Buy	20,000	$76.00	$1,520,000.00

New CBOE “special perk” helps traders target income every weekend

From DTI Trader | Ad

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

Check out this training for the full story!

SEC Filings (Institutional Ownership Changes) for ALX Oncology (NASDAQ:ALXO)

83.37% of ALX Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

ALX Oncology Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/30/2023	American Century Companies Inc.	10,257	$49K	0.0%	N/A	0.021%
11/14/2023	Trexquant Investment LP	14,269	$68K	0.0%	-71.7%	0.035%
11/13/2023	Federated Hermes Inc.	251,360	$1.21M	0.0%	-1.4%	0.611%
11/13/2023	Hsbc Holdings PLC	35,404	$0.17M	0.0%	N/A	0.086%
11/13/2023	FMR LLC	5,591,947	$26.84M	0.0%	-8.8%	13.589%
11/9/2023	Deutsche Bank AG	10,789	$52K	0.0%	-94.4%	0.022%
11/9/2023	UBS Group AG	11,194	$54K	0.0%	-9.4%	0.027%
11/8/2023	Charles Schwab Investment Management Inc.	140,734	$0.68M	0.0%	-15.0%	0.342%
11/8/2023	J.P. Morgan Private Wealth Advisors LLC	20,000	$96K	0.0%	N/A	0.049%
11/8/2023	Forefront Analytics LLC	13,769	$66K	0.0%	N/A	0.033%
11/7/2023	Barclays PLC	26,964	$0.13M	0.0%	+57.1%	0.066%
10/13/2023	SG Americas Securities LLC	10,069	$48K	0.0%	N/A	0.024%
8/21/2023	California State Teachers Retirement System	7,197	$54K	0.0%	-70.1%	0.017%
8/15/2023	Alliancebernstein L.P.	38,580	$0.29M	0.0%	+28.6%	0.094%
8/15/2023	Wells Fargo & Company MN	9,033	$68K	0.0%	+76.9%	0.022%
8/15/2023	Y Intercept Hong Kong Ltd	10,615	$80K	0.0%	N/A	0.026%
8/15/2023	Royal Bank of Canada	4,001	$30K	0.0%	+226.6%	0.010%
8/14/2023	State of Wisconsin Investment Board	98,600	$0.74M	0.0%	+8.8%	0.241%
8/14/2023	State Street Corp	381,419	$2.86M	0.0%	-3.2%	0.933%
8/11/2023	Renaissance Technologies LLC	182,800	$1.37M	0.0%	+44.1%	0.447%
8/11/2023	BlackRock Inc.	1,788,760	$13.43M	0.0%	+7.2%	4.377%
8/11/2023	Trexquant Investment LP	50,431	$0.38M	0.0%	+16.6%	0.123%
8/11/2023	Geode Capital Management LLC	444,298	$3.34M	0.0%	+5.5%	1.087%
8/11/2023	Northern Trust Corp	192,702	$1.45M	0.0%	-2.9%	0.471%
8/10/2023	MetLife Investment Management LLC	11,556	$87K	0.0%	N/A	0.028%
8/10/2023	Charles Schwab Investment Management Inc.	165,551	$1.24M	0.0%	+10.0%	0.405%
8/10/2023	Citigroup Inc.	7,139	$54K	0.0%	+671.8%	0.017%
8/9/2023	Dimensional Fund Advisors LP	89,372	$0.67M	0.0%	-3.3%	0.219%
8/3/2023	Los Angeles Capital Management LLC	146,677	$1.10M	0.0%	+2.2%	0.359%
8/3/2023	Bank of New York Mellon Corp	72,090	$0.54M	0.0%	+4.4%	0.176%
7/25/2023	DekaBank Deutsche Girozentrale	41,000	$0.30M	0.0%	+68.7%	0.100%
5/18/2023	JPMorgan Chase & Co.	17,807	$81K	0.0%	+32.7%	0.044%
5/16/2023	Jane Street Group LLC	22,273	$0.10M	0.0%	N/A	0.054%
5/16/2023	Squarepoint Ops LLC	63,231	$0.29M	0.0%	N/A	0.155%
5/16/2023	Geode Capital Management LLC	421,044	$1.90M	0.0%	+2.1%	1.030%
5/15/2023	Cubist Systematic Strategies LLC	33,869	$0.15M	0.0%	-6.8%	0.083%
5/15/2023	Braidwell LP	1,249,900	$5.65M	0.2%	+383.9%	3.059%
5/15/2023	Logos Global Management LP	1,500,000	$6.78M	1.0%	-36.2%	3.671%
5/15/2023	Two Sigma Advisers LP	120,000	$0.54M	0.0%	+39.9%	0.294%
5/15/2023	Two Sigma Investments LP	108,351	$0.49M	0.0%	+135.5%	0.265%
5/15/2023	Deutsche Bank AG	346,789	$1.57M	0.0%	+1.3%	0.849%
5/15/2023	XTX Topco Ltd	25,817	$0.12M	0.0%	N/A	0.063%
5/12/2023	Renaissance Technologies LLC	126,819	$0.57M	0.0%	+32.4%	0.310%
5/12/2023	BlackRock Inc.	1,668,624	$7.54M	0.0%	-1.9%	4.083%
5/12/2023	Bank of America Corp DE	25,405	$0.12M	0.0%	-87.5%	0.062%
5/12/2023	Prudential Financial Inc.	22,780	$0.10M	0.0%	+21.3%	0.056%
5/12/2023	HRT Financial LP	82,545	$0.37M	0.0%	N/A	0.202%
5/12/2023	UBS Group AG	10,043	$45K	0.0%	+38.7%	0.025%
5/12/2023	Dimensional Fund Advisors LP	92,412	$0.42M	0.0%	+16.6%	0.226%
5/12/2023	Charles Schwab Investment Management Inc.	150,472	$0.68M	0.0%	-5.9%	0.368%
5/12/2023	Forefront Analytics LLC	13,037	$59K	0.0%	N/A	0.032%
5/11/2023	FMR LLC	6,129,441	$27.71M	0.0%	+0.3%	15.000%
5/10/2023	Swiss National Bank	39,500	$0.18M	0.0%	-8.1%	0.097%
5/9/2023	Tower Research Capital LLC TRC	13,694	$62K	0.0%	+1,021.5%	0.034%
5/8/2023	Federated Hermes Inc.	510,666	$2.31M	0.0%	+10.1%	1.250%
5/4/2023	Barclays PLC	15,547	$70K	0.0%	+34.9%	0.038%
5/4/2023	Los Angeles Capital Management LLC	143,507	$0.65M	0.0%	-4.3%	0.351%
2/16/2023	Alliancebernstein L.P.	28,500	$0.32M	0.0%	+12.2%	0.070%
2/15/2023	State of Wisconsin Investment Board	89,790	$1.01M	0.0%	-7.0%	0.220%
2/15/2023	Millennium Management LLC	87,446	$0.99M	0.0%	-62.3%	0.215%
2/15/2023	Morgan Stanley	486,318	$5.48M	0.0%	+22.6%	1.193%
2/15/2023	Alps Advisors Inc.	27,703	$0.31M	0.0%	+24.5%	0.068%
2/15/2023	Braidwell LP	258,280	$2.91M	0.1%	N/A	0.634%
2/14/2023	Point72 Asset Management L.P.	85,000	$0.96M	0.0%	-77.8%	0.209%
2/14/2023	PDT Partners LLC	21,735	$0.25M	0.0%	-40.2%	0.053%
2/14/2023	Two Sigma Investments LP	46,000	$0.52M	0.0%	-56.9%	0.113%
2/13/2023	Charles Schwab Investment Management Inc.	159,985	$1.80M	0.0%	+5.6%	0.393%
2/13/2023	Barclays PLC	11,528	$0.13M	0.0%	+72.7%	0.028%
2/13/2023	Renaissance Technologies LLC	95,800	$1.08M	0.0%	-43.8%	0.235%
2/13/2023	Credit Suisse AG	21,293	$0.24M	0.0%	-18.8%	0.052%
2/13/2023	Geode Capital Management LLC	412,309	$4.65M	0.0%	+4.8%	1.012%
2/10/2023	Bank of America Corp DE	203,074	$2.29M	0.0%	+814.5%	0.498%
2/10/2023	New York Life Investment Management LLC	33,562	$0.38M	0.0%	+12.7%	0.082%
2/9/2023	Mirae Asset Global Investments Co. Ltd.	10,489	$0.12M	0.0%	N/A	0.026%
2/9/2023	Dimensional Fund Advisors LP	79,277	$0.89M	0.0%	+19.3%	0.194%
2/8/2023	UBS Group AG	7,242	$82K	0.0%	N/A	0.018%
2/6/2023	Los Angeles Capital Management LLC	149,932	$1.69M	0.0%	-0.8%	0.368%
12/8/2022	Bank of New York Mellon Corp	69,720	$0.67M	0.0%	+10.5%	0.171%
11/16/2022	Jane Street Group LLC	15,033	$0.14M	0.0%	+15.6%	0.037%
11/16/2022	BNP Paribas Arbitrage SNC	17,380	$0.17M	0.0%	N/A	0.043%
11/15/2022	Alliancebernstein L.P.	25,400	$0.24M	0.0%	-8.6%	0.062%
11/15/2022	State Street Corp	384,563	$3.68M	0.0%	+8.1%	0.944%
11/15/2022	Pier Capital LLC	272,617	$2.61M	0.4%	-31.5%	0.669%
11/15/2022	Two Sigma Advisers LP	109,800	$1.05M	0.0%	-31.7%	0.269%
11/15/2022	Two Sigma Investments LP	106,652	$1.02M	0.0%	-56.4%	0.262%
11/15/2022	Vanguard Group Inc.	1,411,009	$13.50M	0.0%	+6.5%	3.462%
11/15/2022	Logos Global Management LP	2,971,352	$28.44M	3.5%	-5.3%	7.290%
11/15/2022	Marshall Wace LLP	24,177	$0.23M	0.0%	N/A	0.059%
11/15/2022	Martingale Asset Management L P	44,612	$0.43M	0.0%	+6.4%	0.109%
11/15/2022	Eventide Asset Management LLC	902,000	$8.63M	0.2%	N/A	2.213%
11/15/2022	Federated Hermes Inc.	464,714	$4.45M	0.0%	+1.7%	1.140%
11/15/2022	Bank of New York Mellon Corp	69,720	$0.67M	0.0%	+10.5%	0.171%
11/15/2022	BlackRock Inc.	1,670,402	$15.99M	0.0%	+0.5%	4.098%
11/14/2022	Point72 Asset Management L.P.	382,500	$3.66M	0.0%	N/A	0.939%
11/14/2022	Cubist Systematic Strategies LLC	44,754	$0.43M	0.0%	-48.8%	0.110%
11/14/2022	PDT Partners LLC	36,370	$0.35M	0.1%	-64.6%	0.089%
11/14/2022	Renaissance Technologies LLC	170,600	$1.63M	0.0%	-25.1%	0.419%
11/14/2022	Nuveen Asset Management LLC	115,621	$1.11M	0.0%	-1.0%	0.284%
11/14/2022	MetLife Investment Management LLC	11,755	$0.11M	0.0%	N/A	0.029%
11/10/2022	Credit Suisse AG	26,233	$0.25M	0.0%	+73.1%	0.064%

Data available starting January 2016

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Today's Range

Now: $12.26

$10.15

$13.50

50 Day Range

MA: $8.25

$4.81

$12.26

52 Week Range

Now: $12.26

$3.94

$13.50

Volume

3,850,931 shs

Average Volume

352,984 shs

Market Capitalization

$610.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Who are the company insiders with the largest holdings of ALX Oncology?: ALX Oncology's top insider investors include:
Jaume Pons (CEO)
Sophia Randolph (Insider)
Shelly Pinto (CAO)
Peter S Garcia (CFO)
Jason Lettmann (Director)
Lsv Associates, Llc (Major Shareholder)
Learn More about top insider investors at ALX Oncology.
Who are the major institutional investors of ALX Oncology?: ALX Oncology's top institutional shareholders include:
FMR LLC — 13.59%
Federated Hermes Inc. — 0.61%
Charles Schwab Investment Management Inc. — 0.34%
Hsbc Holdings PLC — 0.09%
Barclays PLC — 0.07%
J.P. Morgan Private Wealth Advisors LLC — 0.05%
Learn More about top institutional investors of ALX Oncology stock.
Which major investors are selling ALX Oncology stock?: During the previous quarter, ALXO stock was sold by these institutional investors:
FMR LLC
Deutsche Bank AG
Trexquant Investment LP
Charles Schwab Investment Management Inc.
Federated Hermes Inc.
UBS Group AG
In the previous year, company insiders that have sold ALX Oncology company stock include:
Jaume Pons (CEO)
Sophia Randolph (Insider)
Shelly Pinto (CAO)
Peter S Garcia (CFO)
Learn More investors selling ALX Oncology stock.
Which major investors are buying ALX Oncology stock?: Within the previous quarter, ALXO stock was purchased by institutional investors including:
Hsbc Holdings PLC
J.P. Morgan Private Wealth Advisors LLC
Forefront Analytics LLC
American Century Companies Inc.
SG Americas Securities LLC
Barclays PLC